Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Analyst Recommendations on JOHNSON & JOHNSON
05:34aANALYST RECOMMENDATIONS : AbbVie, Eli Lilly, Johnson & Johnson, Fox, United Airlines...
01/24Morgan Stanley Adjusts Johnson & Johnson's Price Target to $175 from $187, Keeps Equalw..
MT
2021Goldman Sachs Initiates Johnson & Johnson at Neutral With $161 Price Target
MT
2021JOHNSON & JOHNSON : UBS Adjusts Price Target on Johnson & Johnson to $175 From $183 After ..
MT
2021ANALYST RECOMMENDATIONS : Ford, Hilton, IBM, Johnson & Johnson, Netflix...
2021JOHNSON & JOHNSON : Raymond James Adjusts Price Target on Johnson & Johnson to $178 from $..
MT
2021JOHNSON & JOHNSON : Credit Suisse Raises Johnson & Johnson's PT to $200 from $196 After Q3..
MT
2021JOHNSON & JOHNSON : Morgan Stanley Downgrades Johnson & Johnson to Equalweight from Overwe..
MT
2021JOHNSON & JOHNSON : Cantor Fitzgerald Adjusts Johnson & Johnson PT to $215 From $200, Main..
MT
2021JOHNSON & JOHNSON : UBS Adjusts Johnson & Johnson's Price Target to $183 From $180; Neutra..
MT
2021JOHNSON & JOHNSON : Credit Suisse reiterates its Buy rating
MD
2021TODAY'S ANALYST RECOMMENDATIONS : Advanced Micro Devices, AstraZeneca, Bodycote, Medtronic..
2021JOHNSON & JOHNSON : Morgan Stanley Assumes Johnson & Johnson at Overweight with $187 Price..
MT
2021JOHNSON & JOHNSON : DA Davidson Adjusts Price Target on Johnson & Johnson to $188 From $16..
MT
2021JOHNSON & JOHNSON : UBS Adjusts Johnson & Johnson's Price Target to $180 From $170, Mainta..
MT
2021JOHNSON & JOHNSON : SVB Leerink Adjusts Johnson & Johnson's Price Target to $200 From $180..
MT
2021JOHNSON & JOHNSON : Morgan Stanley Adjusts Johnson & Johnson's Price Target to $187 From $..
MT
2021JOHNSON & JOHNSON : Cowen Adjusts Johnson & Johnson's Price Target to $195 From $170, Keep..
MT
2021JOHNSON & JOHNSON : Raymond James Adjusts Johnson & Johnson's Price Target to $183 From $1..
MT
2021JOHNSON & JOHNSON : Cantor Fitzgerald Adjusts Johnson & Johnson's Price Target to $200 Fro..
MT
2021JOHNSON & JOHNSON : Credit Suisse Adjusts Johnson & Johnson's Price Target to $193 from $1..
MT
2021JOHNSON & JOHNSON : Stifel Nicolaus Adjusts Price Target for Johnson & Johnson to $180 Fro..
MT
2021JOHNSON & JOHNSON : Goldman Sachs Adjusts Price Target for Johnson & Johnson to $201 From ..
MT
2021JOHNSON & JOHNSON : JP Morgan Adjusts Price Target for Johnson & Johnson to $175 From $157..
MT
2021JOHNSON & JOHNSON : Wells Fargo Adjusts Johnson & Johnson's Price Target to $190 From $175..
MT
2021JOHNSON & JOHNSON : UBS Adjusts Price Target on Johnson & Johnson to $170 From $160, Maint..
MT
2020JOHNSON & JOHNSON : Zacks Adjusts Johnson & Johnson's Price Target to $161 from $156, Keep..
MT
2020JOHNSON & JOHNSON : Morgan Stanley Adjusts Price Target for Johnson & Johnson to $178 From..
MT
2020JOHNSON & JOHNSON : Credit Suisse gives a Buy rating
MD
2020J&J, Biotech Firm In $6.5 Billion Deal J&J Agrees to Buy Biotech Company -- WSJ
DJ
2020Pharma Companies Split on Coronavirus Vaccine Pricing Plans
DJ
2020JOHNSON & JOHNSON : Beats Analysts' Profit Expectations for 2Q
DJ
2020GENMAB : Darzalex Meets Main Endpoint in Light-Chain Amyloidosis Study
DJ
2020Drugmakers see long road ahead in coronavirus vaccine race
RE
2019J&J recalls 33,000 bottles of baby powder as FDA finds asbestos in sample
RE
2019JOHNSON & JOHNSON : Goldman Sachs maintains a Buy rating
MD
2019JOHNSON & JOHNSON : Credit Suisse reiterates its Buy rating
MD
2019JOHNSON & JOHNSON : J&J warns of hit from generic drugs in third quarter, shares fall
RE
2019JOHNSON & JOHNSON : J&J warns of hit from generic drugs in third quarter, shares fall
RE
2019JOHNSON & JOHNSON : Credit Suisse keeps its Buy rating
MD
2019JOHNSON & JOHNSON : RBC reaffirms its Buy rating
MD
2019GLOBAL MARKETS LIVE : LVMH, Burberry, Facebook, Teslaů
2019Bristol-Myers plans to divest Celgene's psoriasis drug, shares slide
RE
2019Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value
RE
2019Emerging markets to fuel Smith & Nephew revenue growth in 2019
RE
2018Biotech incubator taps investors through in-house brokerage
RE
2018U.S. insurers grilled on exposure to $4.7 billion J&J talc verdict
RE
2018J&J nears diabetes device exit with $2.1 bln LifeScan sale
RE
2018Johnson & Johnson nears diabetes device exit with $2.1 billion LifeScan sale
RE
2018Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom
RE
2018Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
RE
2018Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
RE
2018Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
RE
2017European shares reverse early losses, DAX immune to political worries
RE
2017FTSE weighed down by housebuilders and strong pound
RE
2017U.S. dollar up, yield curve flat, on inflation; stocks rise
RE
2017U.S. dollar up, yield curve flat, on inflation; stocks rise
RE
2017BAYER : Germany's Merck hires JP Morgan to sell consumer health
RE
2017Nestle plan hailed as only the start of Schneider's shake-up
RE
2017Nestle plan hailed as only the start of Schneider's shake-up
RE
2017Stroke drug Xarelto, plastics lift Bayer earnings
RE
2017Johnson & Johnson refills drug cabinet with $30 billion Actelion deal
RE
2017Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal
RE
2016Pfizer to start shipping biosimilar version of J&J's Remicade in November
RE
2016Moody's reviews Microsoft credit rating for cut after LinkedIn deal
RE
2016Cheap oil smudges Exxon's long-held sterling credit rating
RE
2016No quick fix seen for Novartis's troubled Alcon unit
RE
2015Big business on winning side in U.S. top court's major rulings
RE
2015CELLTRION : J&J cuts full-year forecast due to strong dollar
RE
2015AbbVie CEO defends Pharmacyclics deal to sceptical investors
RE
2015Cardinal to buy J&J vascular technology unit Cordis for $1.9 billion
RE
2014Johnson Matthey optimistic for full-year
RE
2014Sodexo cuts sales growth forecast due to contract delays
RE
2014Bayer wins Merck & Co's $14 billion consumer unit auction
RE
2014Bayer wins Merck & Co's $14 billion consumer unit auction
RE
1  2Next
Official Publications
Upcoming event on JOHNSON & JOHNSON